. The time scale over which Ca
2+
-dependent regulation operates ranges from microseconds to hours, and Ca 2+ signals are often highly localized (reviewed by Bootman, Lipp & Berridge, 2001; Augustine, Santamaria & Tanaka, 2003) . Cells have developed exquisitely tuned components for temporal and spatial regulation of free Ca 2+ levels in the cytoplasm (reviewed by Berridge, Bootman & Roderick, 2003) . These mechanisms comprise a "Ca 2+ -signaling toolkit" consisting of a large and diverse collection of signaling units that, alone or in combination with one another, distribute Ca 2+ signals with varying temporal and spatial properties. These signaling units include receptors, channels, pumps and exchangers, Ca 2+ buffers, Ca
-binding proteins, and Ca
-sensitive enzymes and processes (see Fig.1 ). Fig. 1 in Redman et al., 1996) . For example, sarco(endo)plasmic reticulum Ca
-ATPases (SERCAs), intracellular ATP-powered pumps that sequester Ca 2+ into the SR, have been identified in schistosomes. Two S. mansoni SERCAs can be distingushed physiologically (Cunha, Reis & Noël, 1996) and two different S. mansoni SERCA-like cDNAs have been reported (deMendonça et al., 1995) . Expression of one of these SERCA cDNAs, SMA2, rescues SERCA-deficient yeast, and is associated with an internal-membrane-associated, Ca
-dependent ATPase activity with kinetic properties and a pharmacological profile similar to mammalian SERCA isoforms (Talla et al., 1998 (Fig. 2) , discovered in the 1970s, was subsequently introduced for the treatment of schistosomiasis (reviewed by Andrews et al., 1983) . It is a pyrazinoisoquinoline with an asymmetric center, and standard preparations are composed of equal proportions of the active, levo (−) and the inactive, dextro (+) optical isomers. The activity of the (−) enantiomer has been established in experiments performed both in vivo (Andrews et al., 5 1983; Liu et al., 1986; Tanaka et al., 1989; Wu et al., 1991; Xiao et al., 1999) and in vitro (Staudt et al., 1992; Xiao & Catto, 1989) .
Praziquantel has activity against all species of schistosomes and shows minimal side effects. As a consequence, it has become the drug of choice against schistosomiasis. Indeed, with the added benefit of dramatic reductions in price, praziquantel has in essence become the sole antischistosomal agent that is available commercially (Fenwick et al., 2003; Hagan et al., 2004) . Praziquantel is also active against other trematode and cestode infections, though generally not against nematodes (reviewed by Andrews, 1985) , and schistosomes show stageand sex-dependent differences in praziquantel sensitivity (Xiao, Catto & Webster, 1985; Sabah et al., 1986; Pica-Mattoccia & Cioli, 2004) .
Praziquantel effectiveness has been proven repeatedly in large-scale schistosomiasis control efforts in different regions. However, the drug has been severely underutilized in subSaharan Africa (reviewed by Fenwick et al., 2003; Hagan et al., 2004) . The recently inaugurated Schistosomiasis Control Initiative (www.schisto.org) was launched as a response to this problem, and has as its goal the establishment of sustainable schistosomiasis control programs in this neglected region.
Since praziquantel serves in effect as the only antischistosomal treatment in widespread use, the possibility of emerging drug resistance is troubling. Others (see, eg, Cioli, 2000; Doenhoff et al., 2002) have discussed this problem in detail. It is clear, however, that the potential for emerging resistance to praziquantel by schistosomes is of special concern considering that the molecular target and mode of action of the drug remain uncertain. Thus, despite the widespread use of praziquantel and nearly three decades of research, the exact mechanism of praziquantel action is still unresolved (reviewed by Day, Bennett & Pax, 1992; Redman et al., 1996; Harder, 2002; Cioli & Pica-Mattoccia, 2003) .
This review will focus on recent advances in identifying the molecular target of praziquantel, 6 highlighting those experiments that point to a critical role for voltage-gated calcium (Ca   2+   ) channel proteins.
Praziquantel acts selectively against members of the phylum Platyhelminthes.
Accordingly, the molecular target (or targets) for praziquantel might be encoded by a novel gene found exclusively in the flatworms. Schistosome genomes and transcriptomes contain several sequences that show no clearcut homology with genes found in other phyla (reviewed by Hu et al., 2004; LoVerde et al., 2004; McManus et al., 2004; Verjovski-Almeida et al., 2004) . On the other hand, the target for praziquantel might be a member of a gene family found in other phyla as well as in the platyhelminths, but with platyhelminth-specific structural signatures required for interaction with the drug. Even minor differences in critical domains of a protein, including single amino acid alterations, can have major consequences for the functional and pharmacological properties of typical receptors and channels (see, eg, Heinemann, Terlau & Imoto, 1992; Satin et al., 1992) .
Though elucidating the mode of action of praziquantel has proved a daunting task, the effects of the drug on adult schistosomes do provide clues to potential targets for the drug.
Praziquantel produces a well-documented effect on intracellular Ca 2+ levels in adult schistosomes (reviewed by Andrews, 1985; Day, Bennett & Pax, 1992; Redman et al., 1996) .
Within seconds of exposure to the drug, adult schistosomes exhibit a rapid, sustained contraction of the worm's musculature (Fetterer, Bennett & Pax, 1980) and vacuolization and disruption of the parasite tegument (Becker et al., 1980; Mehlhorn et al., 1981) , an effect associated with the subsequent exposure of parasite antigens on the surface of the worm (Harnett & Kusel, 1986) . Both of these responses are thought to be linked to a praziquanteldependent disruption of Ca 2+ homeostasis (reviewed by Day, Bennett & Pax, 1992; Redman et al., 1996) . & Fetterer, 1978; Wolde Mussie et al., 1982; Xiao et al., 1984) . However, neither of these inhibitory effects appear immediately. For example, inhibition of the praziquantel-dependent contraction of the musculature requires at least 10 minutes to occur, a delay thought to correspond to the time required for depletion of sequestered intracellular Ca 2+ stores. These results indicate that though extracellular Ca 2+ is not required for the initiation of praziquanteldependent action, it is required for maintenance of the response.
Based on comparisons between praziquantel response in intact and detegumented parasites, it appears that both the tegument and the sarcolemma contain praziquantel-sensitive sites (Blair, Bennett & Pax, 1992 -free medium produces no muscular contraction. Interestingly, praziquantel (1-2 µM) has been reported to interact with both sarcolemmal and intracellular sites to produce a sustained Ca 2+ -dependent contraction in the penile retractor muscle from the mollusc Lymnaea stagnalis (Gardner & Brezden, 1984) .
The effects of praziquantel on Ca 2+ homeostasis could point to a direct action of the drug on membrane permeability to Ca
. However, early experiments indicated that praziquantel is not acting as a Ca 2+ ionophore (Pax, Bennett & Fetterer, 1978) . On the other hand, it has been reported that praziquantel alters the structure of membrane bilayer phospholipids or membrane fluidity (Harder, Goossens. & Andrews, 1988; Lima et al., 1994) , which could result in changes in membrane permeability to Ca 2+ or to indirect effects on membrane receptors and channels.
The target of praziquantel might also be one of the several cellular factors involved in regulating intracellular levels of Ca 2+ discussed above and reviewed by Redman et al. (1996.) To date, there is little direct evidence implicating or eliminating these factors as possible targets in praziquantel action. However, Cunha & Noël (1997) have reported that high concentrations of praziquantel (100 µM) have no effect on schistosome (Na
Recently, voltage-gated Ca 2+ channels have been identified as candidate targets of praziquantel action (Kohn et al., 2001a (Kohn et al., , 2003a underscored by the fact that organisms as diverse as fish-hunting cone snails and spiders produce toxins targeted against specific Ca 2+ channel subtypes to immobilize prey.
The pore-forming subunit of voltage-gated Ca 2+ channels is the α 1 subunit. In addition to the α 1 subunit, voltage-gated Ca 2+ channels typically contain associated auxiliary subunits that modulate the properties of the channel (see Fig. 3 ). The α 1 subunit is made up of four linked homologous domains, each of which contains six transmembrane regions (S1-S6). The predicted structure of the α 1 subunit fits within the ion channel superfamily (Doyle et al., 1998) . The most basic ion channels are tetrameric structures comprised of the fifth and sixth transmembrane regions (S5 and S6, respectively) and the P loop, a region between S5 and S6 that forms the selectivity filter of the pore. The residues that define a channel's ionic 10 selectivity and many of its pharmacological properties reside in this region. In the voltagegated channels, the fourth transmembrane segment within each domain (S4) contains a positively charged amino acid (lysine or arginine) at every third residue and is thought to serve as the voltage sensor of the channel. In the HVA Ca 2+ channels, the α 1 subunit is associated with and modulated by auxiliary subunits (reviewed by Hofmann, Lacinova & Klugbauer, 1999; Catterall, 2000; Arikkath & Campbell, 2003) that include α 2 /δ and β subunits (Fig. 3) , as well as γ subunits (not shown). Ca 2+ channel β subunits (Ca v βs) are cytoplasmic proteins that have been studied extensively and are critical components of Ca 2+ channel complexes. When coexpressed with β subunits, α 1 subunits show increases in current density and ligand binding. Ca v βs appear to play a role in membrane trafficking of the α 1 subunit, likely in part by masking an ER retention site on the α 1 subunit (Bichet et al., 2000) . β subunits also affect a variety of the biophysical properties of Ca 2+ channels, including the voltage-dependence of channel activation and steady state inactivation, rates of inactivation (reviewed by Walker & DeWaard, 1998; Birnbaumer et al., 1998; Hanlon & Wallace, 2002; Dolphin, 2003) , and the rate of recovery from inactivation (Jeziorski, Greenberg & Anderson, 2000b) .
The primary site on the α 1 subunit for binding of Ca v βs is the Alpha Interaction Domain (AID; Pragnell et al., 1994) , an 18 amino acid region in the intracellular loop between Domains I and II of the α 1 subunit. Recent X-ray crystallographic studies (Chen, et al., 2004; Opatowski et al., 2004; Petegem et al., 2004) indicate that the AID indeed does complex with Ca v βs, forming an amphipathic helix with the most highly conserved residues on one side of the helix in contact with a complementary groove on the β subunit.
Using homology modeling, Hanlon et al. (1999) proposed that Ca v βs are members of the membrane-associated guanylate kinase (MAGUK) family of proteins. MAGUKs are scaffolding proteins, often concentrated at synapses where they play important roles in clustering of ion channels and neurotransmitter receptors (reviewed by Dimitratos et al., 1999) . Typically, MAGUKs contain one or more PDZ domains located N-terminal to a Srchomology 3 (SH3) domain, a bridging region (the HOOK domain), and a guanylate kinase (GK)-like domain. Resolution of the crystal structure of the conserved core of β subunits, both alone and in complex with the AID of the α 1 subunit, are consistent with Ca v βs indeed being members of the MAGUK family, though with distinct characteristics (Chen, et al., 2004; Opatowski et al., 2004; Petegem et al., 2004; commentary by Yue, 2004 Schistosomes (and presumably other platyhelminths) therefore appear to be unique among the invertebrates in that they have two subtypes of non L-type α 1 subunits rather than one.
Schistosomes also express at least two subtypes of Ca v βs (Kohn et al., 2001a; 2003b) .
This finding is also unprecedented among the invertebrates; to date, only a single β subunit gene has been identified in the genomes of other invertebrate species. Even more noteworthy, one of these schistosome β subunit subtypes has particularly unusual structural features and functional properties. To date, no representatives of this variant subtype have been identified in any vertebrates or invertebrates other than the platyhelminths (see Fig. 4 ).
The variant Ca v β subtype proteins are clearly part of the broader β subunit family, although they have very distinct structural features. For example, they are from 25% -50% larger than other β subunits, including the conventional S. mansoni Ca v β. However, the most striking feature of these variant Ca v βs can be found in the BID, where two serine residues that are conserved in other Ca v βs and that correspond to consensus protein kinase C (PKC) phosphorylation sites are replaced by cysteine and alanine (Fig. 5) .
The variant schistosome β subunits also exhibit distinctive functional properties (Kohn et al., 2001a Using site-directed mutagenesis, the specific amino acid residues involved in determining the unusual functional properties and pharmacological sensitivities of the variant β subunits have been localized. Both the reduction in current levels and the responsiveness to praziquantel map to the two conserved consensus PKC sites in the BID that are not present in these variant β subunits (Kohn et al., 2003a, b) . If serine residues are substituted at either or both of these sites in the variant Ca v β from S. mansoni the consensus PKC sites are restored (see Fig. 5 ). This mutated β subunit, like conventional Ca v βs, now enhances currents through α 1 subunits and does not confer sensitivity to praziquantel. A double mutation containing a serine at one of these sites, but also containing a second mutation that eliminates the consensus PKC sequence, behaves like the wildtype schistosome subunit. Thus, the absence of PKC sites in the BID region, rather than simply the presence of residues other than serines, appears to be responsible for the novel effects of the variant subunit. Similarly, elimination of both PKC sites in the BID of a conventional β subunit (mammalian β2a) results in a β subunit that can now confer praziquantel sensitivity to the mammalian α 1 subunit (Kohn et al., 2003b) .
Thus, the absence of consensus PKC sites in the β subunit BID is associated with the capability of a β subunit to confer susceptibility to praziquantel, while the presence of a single consensus PKC site in the BID is sufficient to transform a variant Ca v β into a β subunit with characteristics typically found for conventional β subunits. Based on these results, we have hypothesized that the unusual modulatory properties and pharmacological sensitivities of the variant Ca v βs from schistosomes are dependent on the absence of the consensus PKC phosphorylation sites found in the BIDs of other β subunits.
Phosphorylation of voltage-gated Ca 2+ channel subunits by PKC and other protein kinases plays a central role in regulating channel properties (reviewed by Rossie, 1999; Kamp & Hell, 2000; Keef, Hume & Zhong, 2001) . A recombinant mammalian β2a subunit has been shown to be phosphorylated by PKC, with a stoichiometry estimated to be 1-2 moles of phosphate per mole of β2a protein (Puri et al., 1997) . There are several consensus PKC sites in β subunits, but the exact sites that are phosphorylated by PKC have yet to be defined either in vitro or in vivo.
CONCLUSIONS AND FUTURE QUESTIONS
The variant Ca v βs found in schistosomes appear to be involved in praziquantel action, while the addition of a PKC site in the BID of these subunits can abolish susceptibility to the drug. It therefore follows that one mechanism for schistosomes to acquire praziquantel resistance might be by acquiring one or both of these PKC sites by mutating the cysteine or alanine residues to serine. Schistosome isolates with reported reduction in praziquantel sensitivity have been tested for the presence of these (and other) mutations (Valle et al., 2003) . These isolates did not exhibit changes in primary structure of schistosome β subunits, nor did they show changes in expression levels of those subunits. Thus, a reduction in praziquantel susceptiblity in these strains apparently does not depend on altered Ca v β structures or expression levels. However, since various Egyptian isolates with reduced praziquantel susceptibility show differential stability (William et al., 2001) , there may be alternative pathways for acquiring praziquantel susceptibility, with different strains of parasites acquiring resistance to praziquantel via various mechanisms.
There are several unresolved issues regarding schistosome Ca 2+ channels and their role in praziquantel action. Of primary importance is the need to characterize schistosome Ca 2+ channel α 1 subunits, either alone or in combination with the two schistosome Ca v β subtypes. These experiments will answer several questions, including whether all possible 18 schistosome α 1 /β combinations are capable of forming functional channels. More specifically, are only certain α 1 /β combinations capable of forming praziquantel-sensitive channels, or can any schistosome channel that contains a variant β subunit respond to the drug? Furthermore, which schistosome cells express these combinations? Once specific praziquantel-sensitive channels are identified, the question of precisely how praziquantel acts on these channels will still remain. For example, praziquantel might be interacting directly with the variant β subunit, or it might instead interfere with α 1 /β subunit interactions, or it could be acting indirectly, via effects on interacting proteins or on the membrane itself to affect Ca 2+ channels that contain these variant Ca v βs. Finally, what are the downstream players in the cascade of events that ultimately leads to paralysis and tegumental disruption?
As described above, the components that regulate Ca 2+ homeostasis in cells are connected with one another through a network of interaction and regulation. The components comprising these interdependent networks might also be affected by praziquantel. In schistosomes, these interactions are further complicated by the complexity of the adult tegument and sub-tegumental compartments (see Fig. 1 of Redman et al., 1996) . The tegument of the adult is formed by a membrane that has a double-bilayer structure (McClaren & Hockley, 1977) and is electrically coupled to underlying muscle cells (Thompson, Pax & Bennett, 1982) .
Independent of their role in praziquantel action, the biological function of these variant schistosome Ca v βs is particularly intriguing. All other known β subunits enhance Ca 
